Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Doseology SciencesDOSEF 31 EV-to-EBITDA is -0.61 as of Jul. 31, 2026. GuruFocus rates DOSEF with a GF Score™ of 31/100 and a GF Value™ of $0.29 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 410 Biotechnology companies, Doseology Sciences ranks worse than 243902.2% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Doseology Sciences's enterprise value is $0.53 Mil.
Doseology Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.87 Mil. Therefore, Doseology Sciences's EV-to-EBITDA for today is -0.61.
The historical rank and industry rank for Doseology Sciences's EV-to-EBITDA or its related term are showing as below:
DOSEF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.45 Med: -0.47 Max: 2.04
Current: -0.62
During the past 6 years, the highest EV-to-EBITDA of Doseology Sciences was 2.04. The lowest was -15.45. And the median was -0.47.
DOSEF's EV-to-EBITDA is ranked worse than 100% of 410
companies
in the Biotechnology industry
Industry Median: 11.46
vs DOSEF: -0.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Doseology Sciences's PE Ratio (TTM) for today is calculated as:
Doseology Sciences's share price for today is $0.1114.
Doseology Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.124.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Doseology Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOSEF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Doseology Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doseology Sciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Doseology Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Doseology Sciences's EV-to-EBITDA falls into.
Doseology Sciences's current Enterprise Value is $0.53 Mil.
Doseology Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Doseology Sciences (DOSEF) has a EV-to-EBITDA of -0.61 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Doseology Sciences. According to the industry distribution chart, Doseology Sciences ranks #999999 out of 410 companies in the Biotechnology industry.
Is Doseology Sciences' EV-to-EBITDA too high?
Doseology Sciences' current EV-to-EBITDA is -0.61. Based on the distribution chart, Doseology Sciences ranks #999999 out of 410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Doseology Sciences has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Doseology Sciences' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Doseology Sciences ranks #999999 out of 410 companies for EV-to-EBITDA. This places Doseology Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 11.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.46, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Doseology Sciences. For the Biotechnology industry, the median EV-to-EBITDA is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Doseology Sciences's current EV-to-EBITDA is -0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doseology Sciences stock overvalued right now?
Based on GuruFocus' analysis, Doseology Sciences (DOSEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.29, compared to a current price of $0.11 — trading 61.6% below its estimated fair value. The current EV-to-EBITDA is -0.61. Doseology Sciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Doseology Sciences (DOSEF), the current EV-to-EBITDA is -0.61 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doseology Sciences (DOSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Doseology Sciences stock appears to be undervalued.
The current stock price of $0.11 is trading 61.6% below its estimated GF Value™ of $0.29.
GuruFocus considers Doseology Sciences to be Possible Value Trap.
Key valuation signals for DOSEF:
EV-to-EBITDA: -0.61
GF Value™: $0.29 vs. price of $0.11 (61.6% below fair value)
No single metric tells the full story. See the DOSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. It offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.
31GF Score
Get the complete analysis for DOSEF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOSEF has been successfully added to your 
